NCT06744894View on ClinicalTrials.gov

SIL as Maintenance Therapy in Multiple Myeloma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2030

Conditions
Multiple Myeloma
Interventions
DRUG

Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy

Patients were treated by Selinexor (40mg po qw d1-28) combined with Ixazomib (4mg po on days 1, 8, and 15 in 28-day cycles) and Lenalidomide(10mg po qd d1-21) as Maintenance Therapy.

All Listed Sponsors
lead

Navy General Hospital, Beijing

OTHER